ASTRAZEN Q1 FY27 results at a glance
ASTRAZENECA PHARMA IND LT Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹683 cr |
|---|
| Revenue YoY | +29.7% |
|---|
| Operating profit | ₹43.71 cr |
|---|
| Operating margin | 6.4% |
|---|
| Net profit | ₹37.93 cr |
|---|
| Net profit YoY | -32.1% |
|---|
| Net profit QoQ | -15.5% |
|---|
| Net margin | 5.6% |
|---|
| Basic EPS | ₹15.17 |
|---|
| TTM revenue | ₹2,432 cr |
|---|
| TTM net profit | ₹170 cr |
|---|
| TTM net margin | 7.0% |
|---|
ASTRAZEN Q1 FY27 results: what the numbers say
ASTRAZENECA PHARMA IND LT (ASTRAZEN) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹683 cr and a net profit of ₹37.93 cr, translating into earnings per share of ₹15.17.
Compared with the same quarter a year earlier, revenue grew strongly by +29.7% and net profit declined strongly by -32.1%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹43.71 cr, an operating margin of 6.4% versus 12.3% a year ago — a contraction of 5.9 percentage points.
ASTRAZEN quarter-wise results table
Net profit
₹37.93 cr
-32.1% YoY
Operating profit
₹43.71 cr
-32.3% YoY
ASTRAZENECA PHARMA IND LT (ASTRAZEN) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹683 cr | ₹43.71 cr | ₹37.93 cr | 6.4% | 5.6% | ₹15.17 | -32.1% | -15.5% |
| Q4 FY262026-03-31 | ₹579 cr | ₹55.31 cr | ₹44.88 cr | 9.6% | 7.8% | ₹17.95 | — | +37.7% |
| Q3 FY262025-12-31 | ₹612 cr | ₹40.99 cr | ₹32.59 cr | 6.7% | 5.3% | ₹13.04 | — | -39.9% |
| Q2 FY262025-09-30 | ₹559 cr | ₹72.61 cr | ₹54.22 cr | 13.0% | 9.7% | ₹21.69 | — | -2.9% |
| Q1 FY262025-06-30 | ₹526 cr | ₹64.54 cr | ₹55.83 cr | 12.3% | 10.6% | ₹22.33 | — | — |
| TTM (last 4 quarters) | ₹2,432 cr | ₹213 cr | ₹170 cr | 8.7% | 7.0% | ₹67.85 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
ASTRAZEN quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
ASTRAZENECA PHARMA IND LT quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹683 cr | ₹579 cr | ₹612 cr | ₹559 cr | ₹526 cr |
|---|
| Total expenses | ₹639 cr | ₹523 cr | ₹571 cr | ₹486 cr | ₹462 cr |
|---|
| Gross profit | ₹236 cr | ₹184 cr | ₹245 cr | ₹235 cr | ₹231 cr |
|---|
| Operating profit (EBIT) | ₹43.71 cr | ₹55.31 cr | ₹40.99 cr | ₹72.61 cr | ₹64.54 cr |
|---|
| Operating margin | 6.4% | 9.6% | 6.7% | 13.0% | 12.3% |
|---|
| Interest cost | ₹1.95 cr | ₹2.04 cr | ₹1.06 cr | ₹0.67 cr | ₹0.72 cr |
|---|
| Profit before tax | ₹50.75 cr | ₹58.14 cr | ₹46.54 cr | ₹72.82 cr | ₹74.7 cr |
|---|
| Tax expense | ₹12.82 cr | ₹13.26 cr | ₹13.95 cr | ₹18.6 cr | ₹18.87 cr |
|---|
| Effective tax rate | 25.3% | 22.8% | 30.0% | 25.5% | 25.3% |
|---|
| Net profit (PAT) | ₹37.93 cr | ₹44.88 cr | ₹32.59 cr | ₹54.22 cr | ₹55.83 cr |
|---|
| Net profit margin | 5.6% | 7.8% | 5.3% | 9.7% | 10.6% |
|---|
| Basic EPS | ₹15.17 | ₹17.95 | ₹13.04 | ₹21.69 | ₹22.33 |
|---|
| Diluted EPS | ₹15.17 | ₹17.95 | ₹13.04 | ₹21.69 | ₹22.33 |
|---|
ASTRAZEN results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +29.7% | — | — | — | — |
|---|
| Revenue QoQ | +18.0% | -5.4% | +9.4% | +6.2% | — |
|---|
| Operating profit YoY | -32.3% | — | — | — | — |
|---|
| Operating profit QoQ | -21.0% | +34.9% | -43.5% | +12.5% | — |
|---|
| Net profit YoY | -32.1% | — | — | — | — |
|---|
| Net profit QoQ | -15.5% | +37.7% | -39.9% | -2.9% | — |
|---|
| EPS YoY | -32.1% | — | — | — | — |
|---|
| EPS QoQ | -15.5% | +37.7% | -39.9% | -2.9% | — |
|---|
ASTRAZEN annual results history
Full-year performance for ASTRAZENECA PHARMA IND LT, useful for reading each quarter in context.
ASTRAZENECA PHARMA IND LT annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹2,273 cr | ₹1,713 cr | ₹1,296 cr | ₹1,003 cr |
|---|
| Total expenses | ₹2,038 cr | ₹1,498 cr | ₹1,124 cr | ₹854 cr |
|---|
| Gross profit | ₹784 cr | ₹713 cr | ₹622 cr | ₹578 cr |
|---|
| Operating profit (EBIT) | ₹235 cr | ₹215 cr | ₹171 cr | ₹149 cr |
|---|
| Operating margin | 10.3% | 12.5% | 13.2% | 14.8% |
|---|
| Interest cost | ₹4.49 cr | ₹1.46 cr | ₹1.2 cr | ₹0.63 cr |
|---|
| Profit before tax | ₹252 cr | ₹156 cr | ₹220 cr | ₹134 cr |
|---|
| Tax expense | ₹64.68 cr | ₹40.62 cr | ₹58.03 cr | ₹34.81 cr |
|---|
| Effective tax rate | 25.6% | 26.0% | 26.4% | 26.0% |
|---|
| Net profit (PAT) | ₹188 cr | ₹116 cr | ₹162 cr | ₹99.29 cr |
|---|
| Net profit margin | 8.3% | 6.8% | 12.5% | 9.9% |
|---|
| Basic EPS | ₹75.00 | ₹46.30 | ₹64.60 | ₹39.70 |
|---|
| Diluted EPS | ₹75.00 | ₹46.30 | ₹64.60 | ₹39.70 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹683 cr against ₹526 cr in Q1 FY26, and ₹579 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +18.0%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹639 cr, or 93.6% of revenue, with operating profit declined -32.3% year on year.
Margins, tax and profitability
Net profit of ₹37.93 cr works out to a net margin of 5.6% compared with 10.6% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, ASTRAZENECA PHARMA IND LT reported profit before tax of ₹50.75 cr, a tax charge of ₹12.82 cr (effective rate 25.3%), interest cost of ₹1.95 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹44.88 cr in Q4 FY26 to ₹37.93 cr in Q1 FY27, a change of -15.5%.
Trailing twelve months and annual context
Across the trailing four quarters ASTRAZENECA PHARMA IND LT has generated revenue of ₹2,432 cr and net profit of ₹170 cr, a trailing net margin of 7.0%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹2,273 cr with net profit of ₹188 cr and EPS of ₹75.00, versus the prior year where revenue grew +32.6% and profit grew +62.0%.
What to watch in the next ASTRAZEN quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
ASTRAZENECA PHARMA IND LT has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
ASTRAZEN results coverage
No results report published for ASTRAZEN yet — our desk covers each quarter within minutes of the filing.
More on ASTRAZEN
ASTRAZEN quarterly results FAQs
What were ASTRAZENECA PHARMA IND LT (ASTRAZEN) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), ASTRAZENECA PHARMA IND LT reported revenue of ₹683 cr and net profit of ₹37.93 cr, a change of -32.1% year on year on +29.7% revenue growth. EPS stood at ₹15.17.
What is ASTRAZEN profit margin in Q1 FY27?
ASTRAZENECA PHARMA IND LT posted a net profit margin of 5.6% and an operating margin of 6.4% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹2,432 cr and net profit ₹170 cr.
Did ASTRAZEN results beat the previous quarter?
ASTRAZENECA PHARMA IND LT net profit changed -15.5% quarter on quarter, from ₹44.88 cr in Q4 FY26 to ₹37.93 cr in Q1 FY27.
When are ASTRAZENECA PHARMA IND LT (ASTRAZEN) quarterly results?
ASTRAZENECA PHARMA IND LT has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see ASTRAZEN latest quarterly results?
Results coverage for ASTRAZEN will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the ASTRAZEN stock page.
What is ASTRAZENECA PHARMA IND LT annual revenue and profit?
For FY26, ASTRAZENECA PHARMA IND LT reported full-year revenue of ₹2,273 cr and net profit of ₹188 cr, with EPS of ₹75.00.
How many quarterly results has ASTRAZEN declared recently?
Past results dates for ASTRAZEN will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
